Merck & Co., Inc. reported 12 positions worth $522.64M for the quarter ended Jun 30, 2026, up 61.9% on the prior quarter. It opened 1 new position, added to 0, trimmed 0 and exited 0. Its largest holding is Personalis, Inc. at 36% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| TRDA Entrada Therapeutics, Inc. | +1.74M | – | $12.80M | 2.45% |
No positions were reduced this quarter.
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| TRDA Entrada Therapeutics, Inc. | +1.74M | $12.80M | 2.45% |
No positions were closed this quarter.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | PSNL Personalis, Inc. | Healthcare | 14.04M | $188.20M | 36.01% | 0 | 0.0% | Unchanged | 13.2% |
| 2 | MRNA Moderna, Inc. | Healthcare | 2.31M | $161.64M | 30.93% | 0 | 0.0% | Unchanged | 0.58% |
| 3 | KYMR Kymera Therapeutics, Inc. | Healthcare | 772.2K | $88.54M | 16.94% | 0 | 0.0% | Unchanged | 0.79% |
| 4 | AKTS Aktis Oncology, Inc. | Healthcare | 952.8K | $30.71M | 5.88% | 0 | 0.0% | Unchanged | 1.72% |
| 5 | EIKN Eikon Therapeutics, Inc. | Healthcare | 1.67M | $21.75M | 4.16% | 0 | 0.0% | Unchanged | 3.08% |
| 6 | TRDA Entrada Therapeutics, Inc. | Healthcare | 1.74M | $12.80M | 2.45% | +1.74M | – | New | 4.12% |
| 7 | STRO Sutro Biopharma, Inc. | Healthcare | 272.4K | $9.04M | 1.73% | 0 | 0.0% | Unchanged | 1.64% |
| 8 | ALEC Alector, Inc. | Healthcare | 3.55M | $7.13M | 1.36% | 0 | 0.0% | Unchanged | 3.18% |
| 9 | VRDN Viridian Therapeutics, Inc.\DE | Healthcare | 93.4K | $1.72M | 0.328% | 0 | 0.0% | Unchanged | 0.08% |
| 10 | XLO Xilio Therapeutics, Inc. | Healthcare | 106.0K | $1.02M | 0.194% | 0 | 0.0% | Unchanged | 0.55% |
| 11 | HURA TuHURA Biosciences, Inc. | Healthcare | 19.4K | $45.50K | <0.01% | 0 | 0.0% | Unchanged | 0.03% |
| 12 | NEUP Neuphoria Therapeutics Inc. | Healthcare | 10.0K | $43.82K | <0.01% | 0 | 0.0% | Unchanged | 0.01% |
Tip. Select a row to see that position’s full history at Merck.
As of its Q2 2026 13F filing, Merck & Co., Inc.’s five largest positions were Personalis, Inc. (PSNL) at 36.0%, Moderna, Inc. (MRNA) at 30.9%, Kymera Therapeutics, Inc. (KYMR) at 16.9%, Aktis Oncology, Inc. (AKTS) at 5.9%, Eikon Therapeutics, Inc. (EIKN) at 4.2% of the reported portfolio.
Merck & Co., Inc. reported a 13F portfolio worth $522.64M across 12 positions for Q2 2026. That is up 61.9% from the previous quarter.
Its largest purchases by value were Entrada Therapeutics, Inc. ($12.80M). It opened 1 new positions.
From the Form 13F-HR reports Merck & Co., Inc. files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.